About Glionova
Glionova was a Healthcare company based in Stockholm (Sweden) founded in 2014. It develops innovative technologies for novel therapies targeting glioblastoma. It operates on a B2B model. Glionova has raised $5.7 million across 2 funding rounds from investors including Vinnova, Healthcap and Industrifonden. The company is recorded as dissolved. Its focus areas include Biotechnology, Therapeutics and Cancer Treatments. Its competitors include GT Medical Technologies, Imvax, Basilea, SOM Biotech and Laminar Pharma and 4 more; 6 of its 9 listed competitors have raised funding.
Company details
Glionova, established in 2014 and currently in Dissolved stage, focuses on providing healthcare solutions, advancing biotech innovations, therapeutics, and cancer treatments. Develops innovative technologies for novel therapies targeting glioblastoma. Adapting to market demands with innovation and client-focused strategies. It continues to evolve, meeting industry challenges with strategic approaches.
- Headquarters Stockholm, Sweden
- SectorsHealthcare
- Website glionova.com
- Social X
- Total Equity Funding$5.7M (USD)
in 2 rounds
- Latest Funding Round$608.08K (USD), Grant
Nov 2014
- InvestorsVinnova
& 3 more
Funding Insights of Glionova
Glionova has successfully raised a total of $5.7M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $608.08 thousand completed in November 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5.7M
- Total Rounds 2
- Last Round Grant — $608,083
- First Round $5.7M
(Nov 2014)
- Investors Count 4
All 2 funding rounds of Glionova with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2014 | $608,083 | Grant | – | – | |
| Nov 2014 | $5.7M | Series A | – | Novo Holdings |
4 investors in total: 4 institutional.
Investors in Glionova
Glionova has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Vinnova, Healthcap and Industrifonden.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital funding is provided to Swedish companies across sectors. | 2001 | vinnova.se | Stockholm, Sweden | |
- | – | healthcap.eu | - | |
Investments in deep-tech, life sciences, and transformative tech are managed. | – | industrifonden.com | Stockholm, Sweden | |
Private equity and venture capital fund focused on the healthcare sector | – | novoholdings.dk | Hellerup, Denmark |
Investor details for Glionova
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Glionova
3 dated milestones of Glionova, from founding to its latest funding, stage changes and deals.
- Founded Glionova is founded.
- Funding First funding round of $5.7M.
- Funding Latest funding round, Grant, of $608K.
Competitors of Glionova
Glionova has 9 listed competitors in our database, 6 of them funded. They include GT Medical Technologies, Imvax, Basilea, SOM Biotech and Laminar Pharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gtmedtech.com | 2017 | Tempe, United States | $129.94M | 29 | Medical devices for brain tumor radiation therapy are provided. | |
| imvax.com | 2015 | Philadelphia, United States | $203.83M | 50 | Patient-specific cell vaccines for glioma treatment are developed. | |
| basilea.com | 1999 | Basel, Switzerland | – | – | Antibiotics, antifungals, and oncology drugs are developed for disease treatment. | |
| sombiotech.com | 2009 | Barcelona, Spain | $28.52M | – | Developer of platform for screening compounds to treat rare diseases | |
| laminarpharma.com | 2006 | Palma, Spain | $14.71M | – | Melipathy-based drugs are developed for cancer, Alzheimer's, and inflammation treatments. | |
| entrinsicbioscience.com | 2012 | Norwood, United States | $19.2M | – | Drugs for tumors, cystic fibrosis, and hemochromatosis are developed. | |
| biodexapharma.com | 2000 | Cardiff, United Kingdom | $6.79M | – | Therapeutics for aggressive rare brain cancers are developed. | |
| curativebiotech.com | 1995 | Boca Raton, United States | – | – | Therapeutic drugs for cancer, eye, and infectious diseases are developed. | |
| cnspharma.com | 2017 | Houston, United States | – | 5 | Treatments for brain and central nervous system cancers are developed. |
Detailed competitors of Glionova
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
10 companies that operate in the same segment as Glionova (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Glionova
Complete news archive for Glionova
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Glionova
Glionova was founded in 2014.
Glionova is headquartered in Stockholm, Sweden.
Glionova is a funded company, having raised a total of $5.7M across 2 funding rounds to date. The company's 1st funding round was a Series A of $5.7M, raised on Nov 2014.
Glionova, established in 2014 and currently in Dissolved stage, focuses on providing healthcare solutions, advancing biotech innovations, therapeutics, and cancer treatments. Develops innovative technologies for novel therapies targeting glioblastoma. Adapting to market demands with innovation and client-focused strategies. It continues to evolve, meeting industry challenges with strategic approaches.
Glionova's top competitors include Imvax, GT Medical Technologies and Basilea.
Glionova has 4 investors. Key investors include Vinnova, Healthcap, Industrifonden, and Novo Holdings.